73 reports of this reaction
1.5% of all SUCCINYLCHOLINE CHLORIDE reports
#20 most reported adverse reaction
RHABDOMYOLYSIS is the #20 most commonly reported adverse reaction for SUCCINYLCHOLINE CHLORIDE, manufactured by Hospira, Inc.. There are 73 FDA adverse event reports linking SUCCINYLCHOLINE CHLORIDE to RHABDOMYOLYSIS. This represents approximately 1.5% of all 4,806 adverse event reports for this drug.
Patients taking SUCCINYLCHOLINE CHLORIDE who experience rhabdomyolysis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RHABDOMYOLYSIS is a less commonly reported adverse event for SUCCINYLCHOLINE CHLORIDE, but still significant enough to appear in the safety profile.
In addition to rhabdomyolysis, the following adverse reactions have been reported for SUCCINYLCHOLINE CHLORIDE:
The following drugs have also been linked to rhabdomyolysis in FDA adverse event reports:
RHABDOMYOLYSIS has been reported as an adverse event in 73 FDA reports for SUCCINYLCHOLINE CHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RHABDOMYOLYSIS accounts for approximately 1.5% of all adverse event reports for SUCCINYLCHOLINE CHLORIDE, making it a notable side effect.
If you experience rhabdomyolysis while taking SUCCINYLCHOLINE CHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.